Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Aviragen Therapeutics Inc (NASDAQ:AVIR)

Delayed Data
As of Aug 29
 -0.0146 / -1.08%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Aviragen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening infectious diseases. The Company currently has two Phase 2 clinical-stage product candidates in development: laninamivir octanoate, a long-acting neuraminidase inhibitor that the Company is developing for the treatment of influenza A and B infections under an investigational new drug application (IND) in the United States through a contract with the U.S. Office of Biomedical Advanced Research and Development Authority (BARDA) that is designed to provide up to $231 million in financial support to complete its clinical development; and vapendavir, a potent, oral broad spectrum capsid inhibitor of enteroviruses, including human rhinovirus (HRV). In addition to these clinical-stage programs, the Company has a preclinical program focused on developing treatments for respiratory syncytial virus (RSV). Aviragen Therapeutics was founded on November 8, 2012 and is headquartered in Alpharetta, GA.

Contact Information

Aviragen Therapeutics, Inc.
2500 Northwinds Parkway
Alpharetta Georgia 30009
P:(678) 221-3343
Investor Relations:



Mutual fund holders7.29%
Other institutional28.24%
Individual stakeholders0.96%

Top Executives

Joseph M. PattiPresident, Chief Executive Officer & Director
Mark P. ColonneseChief Financial Officer & Executive Vice President
Anna Novotney-BarryVice President-Clinical Development
John H. VernachioVice President-Preclinical Development
Jonas NiauraVice President-Corporate Development & Strategy